NYSE$BMY
Bristol-Myers Squibb Co · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported a decline in revenue due to lower sales of Revlimid, partially offset by in-line products and new product portfolio, and revised outlook for total revenues and GAAP and non-GAAP EPS due to lower expected revenues for Revlimid and Pomalyst.
Bristol Myers Squibb reported second-quarter revenues of $11.2 billion, a 6% decrease year-over-year, primarily due to a rapid decline in Revlimid sales. The company is revising its full-year financial guidance due to this decline but reaffirms its 2020-2025 financial targets and announces a $4 billion accelerated share repurchase agreement.
- Second quarter revenues were reported at $11.2 billion.
- GAAP earnings per share were $0.99, and non-GAAP EPS was $1.75, including a net impact of ($0.05) per share due to acquired IPRD charges and licensing income.
- Revenue growth for in-line products and the new product portfolio was 4%.
- The outlook for total revenues has been revised to a low single-digit decline, GAAP EPS to $3.72-$4.02, and non-GAAP EPS to $7.35-$7.65 due to lower expected revenues for Revlimid and Pomalyst.
Headline financials
Revenue & EPS history
Bristol-Myers Squibb · Revenue · Quarterly
$11.2B
Forward guidance
Bristol Myers Squibb is revising its 2023 guidance, adjusting the outlook for total revenues and GAAP and non-GAAP EPS primarily due to lower than expected sales of Revlimid, and to a lesser extent, Pomalyst.
Tailwinds
- Total revenues are expected to decline by a low single-digit.
- Total revenues excluding foreign exchange impact are expected to decline by a low single-digit.
- Gross margin is projected to be approximately 76%.
- Operating expenses are expected to decline by a low single-digit.
- The effective tax rate is anticipated to be around 16%.
Headwinds
- Revenues from Revlimid are now expected to be approximately $5.5 billion.
- GAAP EPS is projected to be between $3.72 and $4.02.
- Non-GAAP EPS is projected to be between $7.35 and $7.65.
- The guidance excludes the impact of any potential future strategic acquisitions and divestitures.
- The guidance is subject to risks and uncertainties applicable to all forward-looking statements.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
-0.1%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+0.9%
Avg return
30 days after
47%
34 / 73 earnings
Positive
+8.2%
Q2 2024
Best reaction
-9.9%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.9% | -1.1% | -0.7% | |
| Q4 2025 | +3.3% | +5.6% | +4.6% | |
| Q3 2025 | +7.1% | +7.0% | +15.5% | |
| Q2 2025 | -5.8% | -0.3% | +2.6% | |
| Q1 2025 | +0.4% | +1.4% | -3.5% | |
| Q4 2024 | -3.8% | -6.3% | +2.3% | |
| Q3 2024 | +3.2% | +6.2% | +12.5% | |
| Q2 2024 | +8.2% | +5.1% | +6.3% | |
| Q1 2024 | -8.2% | -10.1% | -15.6% | |
| Q4 2023 | -1.4% | -0.1% | +4.6% | |
| Q3 2023 | -9.9% | -9.0% | -12.1% | |
| Q2 2023 | -3.2% | -3.0% | -2.1% | |
| Q1 2023 | -1.8% | +0.1% | -6.2% | |
| Q4 2022 | +4.5% | +4.6% | -2.7% | |
| Q3 2022 | +2.0% | +5.3% | +8.4% | |
| Q2 2022 | +1.5% | -0.0% | -3.3% | |
| Q1 2022 | -2.7% | -1.2% | -1.4% | |
| Q4 2021 | +3.3% | +4.8% | +8.3% | |
| Q3 2021 | -1.9% | +0.8% | -2.9% | |
| Q2 2021 | +1.0% | +0.8% | -1.3% | |
| Q1 2021 | -5.5% | -3.2% | -0.5% | |
| Q4 2020 | -1.8% | -3.7% | -2.6% | |
| Q3 2020 | -2.5% | -1.4% | -4.8% | |
| Q2 2020 | +2.2% | +5.8% | +0.4% | |
| Q1 2020 | -0.1% | +3.6% | +0.3% | |
| Q4 2019 | +1.0% | +2.1% | -8.1% | |
| Q3 2019 | +0.5% | -0.8% | +0.1% | |
| Q2 2019 | +5.0% | +3.1% | +7.7% | |
| Q1 2019 | +2.8% | +4.1% | +4.9% | |
| Q4 2018 | -2.1% | -3.3% | +2.0% | |
| Q3 2018 | +3.3% | +2.4% | +8.4% | |
| Q2 2018 | -3.6% | -0.5% | +1.6% | |
| Q1 2018 | +1.0% | +1.8% | +2.0% | |
| Q4 2017 | -4.1% | -1.2% | +4.1% | |
| Q3 2017 | -6.3% | -3.7% | -4.0% | |
| Q2 2017 | -1.3% | +0.2% | +4.3% | |
| Q1 2017 | +4.2% | +4.1% | +0.4% | |
| Q4 2016 | -3.7% | -0.8% | +13.9% | |
| Q3 2016 | +3.5% | +3.1% | +15.6% | |
| Q2 2016 | -2.2% | -1.9% | -23.1% | |
| Q1 2016 | +2.8% | — | — | |
| Q4 2015 | +0.7% | — | — | |
| Q3 2015 | +4.7% | — | — | |
| Q2 2015 | -4.9% | — | — | |
| Q1 2015 | -1.3% | — | — | |
| Q4 2014 | -1.8% | — | — | |
| Q3 2014 | +2.0% | — | — | |
| Q2 2014 | +0.1% | — | — | |
| Q1 2014 | -0.5% | — | — | |
| Q4 2013 | -7.8% | — | — | |
| Q3 2013 | -0.7% | — | — | |
| Q2 2013 | -0.8% | — | — | |
| Q1 2013 | -2.8% | — | — | |
| Q4 2012 | +5.1% | — | — | |
| Q3 2012 | +1.5% | — | — | |
| Q2 2012 | +3.1% | — | — | |
| Q1 2012 | -0.6% | — | — | |
| Q4 2011 | +0.9% | — | — | |
| Q3 2011 | -1.3% | — | — | |
| Q2 2011 | +0.2% | — | — | |
| Q1 2011 | -0.0% | — | — | |
| Q4 2010 | -1.5% | — | — | |
| Q4 2007 | -1.5% | — | — | |
| Q3 2010 | -1.1% | — | — | |
| Q2 2010 | -0.4% | — | — | |
| Q1 2009 | +4.0% | — | — | |
| Q1 2010 | +0.7% | — | — | |
| Q4 2009 | -0.6% | — | — | |
| Q3 2008 | -2.0% | — | — | |
| Q3 2009 | -2.0% | — | — | |
| Q4 2008 | +5.5% | — | — | |
| Q2 2008 | +5.5% | — | — | |
| Q2 2009 | +5.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro